Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.16 estudios en Programa de terapia de células T con receptores de antígeno quimérico (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Subjects who received at least one GM T cell infusion, will be asked to roll-over to this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol. Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers Rochester, Minn. A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers. PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Rochester, Minn. The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome. A Study to Evaluate the Safety and Effectiveness of Lisocatagene Maraleucel in Patients Rochester, Minn., Jacksonville, Fla. The purpose of this study is to assess the safety of nonconforming lisocabtagene maraleucel in patients, and to assess the effectiveness of nonconforming lisocabtagene maraleucel in patients. A Study to Evaluate the Effectiveness and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the effectiveness and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1) and in subjects with HR MM having progressed within one year of initial treatment (Cohort 2). Approximately 122 subjects will be enrolled into one of two cohorts. Cohort 1 will enroll approximately 73 RRMM subjects with ≥ 3 prior anti-myeloma treatment regimens. Cohort 2 will enroll approximately 49 MM subjects with 1 prior anti-myeloma treatment regimen and HR disease defined as Stage III by the Revised International Staging System (R-ISS) and early relapse. The cohorts will start in parallel and independently. AUTO1 in Relapsed or Refractory B-ALL Rochester, Minn. The purpose of this study is to evaluate the safety and effectiveness of AUTO1 (t-cells) in adult patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (r/r B-ALL). Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 11 Ir a página 22 Solicite una consulta Preguntas frecuentesRemisiones Feb. 19, 2022 Comparte en: FacebookTwitter Programa de terapia de células T con receptores de antígeno quiméricoPágina inicialdel departamentoSeccionesDescripción generalInformación sobre el tratamiento de células T con receptores de antígenos quiméricosNuestro programaMédicosPreguntas frecuentesEnsayos clínicosRemisiones Investigación: todo es por los pacientes Mostrar la transcripción Para video Investigación: todo es por los pacientes [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SeccionesSolicite una ConsultaDescripción generalInformación sobre el tratamiento de células T con receptores de antígenos quiméricosNuestro programaMédicosPreguntas frecuentesEnsayos clínicosRemisiones ORG-20404311 Centros y departamentos médicos Programa de terapia de células T con receptores de antígeno quimérico